Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112375 | 0.79 | TSHR (0.58) | TSHRALDH1A1AOC3MAPK1CARM1 | |
| Hydrochloric Acid SCHEMBL31556140 | 0.77 | TSHR (0.56) | TSHRALDH1A1AOC3CARM1PRMT6 | |
| SCHEMBL10660626 | 0.76 | TSHR (0.54) | TSHRALDH1A1AOC3MAPK1CARM1 | |
| SCHEMBL400749 | 0.76 | TSHR (0.54) | TSHRALDH1A1AOC3MAPK1CARM1 | |
| Hydrochloric Acid SCHEMBL7899272 | 0.74 | TSHR (0.52) | TSHRALDH1A1AOC3MAPK1CARM1 | |
| SCHEMBL294642 | 0.73 | TSHR (0.64) | TSHRALDH1A1AOC3CARM1PRMT6 | |
| SCHEMBL9545622 | 0.73 | TSHR (0.50) | TSHRALDH1A1AOC3MAPK1CARM1 | |
| SCHEMBL5462064 | 0.72 | TSHR (0.55) | TSHRALDH1A1AOC3CARM1PRMT6 | |
| SCHEMBL1776018 | 0.72 | TSHR (0.55) | TSHRALDH1A1AOC3CARM1PRMT6 | |
| SCHEMBL9853509 | 0.71 | TSHR (0.50) | TSHRALDH1A1AOC3MAPK1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222187-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2004-09-22 | — | — | EP | claimed |
| US-6770639-B2 | CELL PROLIFERATIVE; AUTOIMMUNE DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | claimed |
| JP-2003527328-A | — | — | 2003-09-16 | — | — | JP | claimed |
| US-6506769-B2 | Pyridine -imidazole, -thiazole or -oxazole derivatives; treating autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| EP-1222187-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-07-17 | — | — | EP | claimed |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2001025238-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | claimed |
| US-4617401-A | ANTISPASMODIC AGENTS, VASODILATORS | SUNTORY LTD. (JP) | 1986-10-14 | — | — | US | claimed |
| EP-0039903-B1 | 8-SUBSTITUTED PYRROLIZIDINES AND QUATERNARY AMMONIUM SALTS THEREOF | SUNTORY KABUSHIKI KAISHA (JP) | 1986-04-09 | — | — | EP | claimed |
| EP-0039903-A2 | 8-Substituted pyrrolizidines and quaternary ammonium salts thereof | SUNTORY KABUSHIKI KAISHA (JP) | 1981-11-18 | — | — | EP | claimed |
| EP-1222187-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6770639-B2 | CELL PROLIFERATIVE; AUTOIMMUNE DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6506769-B2 | Pyridine -imidazole, -thiazole or -oxazole derivatives; treating autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1222187-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001025238-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | TSHR 1362/4885ALDH1A1 1139/4885AOC3 1212/4885 |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | TSHR 1362/4885ALDH1A1 1139/4885AOC3 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.